Paralysis is the loss of the ability of one or more muscles to move, due to disruption of signaling between the nervous system and muscles. The most common causes of paralysis are stroke, head injury, spinal cord injury (SCI) and multiple sclerosis. The search for cure of paralysis is yet to be found. Many ethnobotanical surveys have reported the use of medicinal plants by various ethnic communities in treating and curing paralysis. The present review discusses the use of medicinal plants in India for ameliorating and curing paralytic conditions, as well as discuses some of the important developments in future possible applications of medicinal plants in treatment of paralysis. This review reports the use of 37 medicinal plants for their application and cure of ailments related to paralysis. Out of the 37 plants documented, 11 plants have been reported for their ability to cure paralysis. However, the information on the documented plants were mostly found to be inadequate, requiring proper authentication with respect to their specificity, dosage, contradictions etc. It is found that despite the claims presented in many ethnobotanical surveys, the laboratory analysis of these plants remain untouched. It is believed that with deeper intervention on analysis of bioactive compounds present in these plants used by ethic traditional healers for paralysis, many potential therapeutic compounds can be isolated for this particular ailment in the near future.
Introduction
Paralysis is a disease related to nervous disorder caused by damage of nerves and spinal cord that control muscles. The most common causes of paralysis are stroke, head injury, spinal cord injury, broken neck and multiple sclerosis. 1 Other causes of paralysis include nerve diseases such as amyotrophic lateral sclerosis, autoimmune diseases such as Guillain-Barre syndrome, Bell's palsy, which affects muscles in the face, and Polio virus. 2 Paralysis can be of localized form, where a specific section of the body is paralyzed, such as the facial paralysis (Bell's Palsy) and paralysis of hand, or generalized form where a larger area of the body is affected, such as the condition where one limb is paralyzed or where the arm and leg on one side of the body are paralyzed. Therefore, depending on the condition and body part(s) affected by paralysis, a number of medical terms are used to describe different types of paralysis. Examples are namely, monoplegia e where one limb is paralyzed, hemiplegia e where the arm and leg on one side of the body are paralyzed, paraplegia e where both legs and sometimes the pelvis and some of the lower body are paralyzed, tetraplegia e where both the arms and legs are paralyzed (also known as quadriplegia). Paralysis when left untreated for a long period could lead to the 'death' of the affected part i.e. wasting of muscles and tissues. Paralysis can also cause a number of associated secondary conditions, such as urinary incontinence (an inability to control the flow of urine) and bowel incontinence (where stools leak from the back passage). It may also affect sexual function in both men and women. In cases of permanent paralysis, treatment aims mostly at assisting a person live as independently as possible by addressing any associated complications that arise from paralysis, such as pressure ulcers (sores that develop when the affected area of tissue is placed under too much pressure), bladder and bowel problems, and treating spasms and complications resulting from paralysis. Mobility aids such as wheelchairs and orthoses can help a person with paralysis. 1 However, all these forms of treatment mostly deodara and Rubia cordifolia in paralysis is also reported. 20, 21 Apart from these well known reports from different forms of alternative medicines for their application of paralysis, the present review emphasizes on the various ethnobotanical documentation of medicinal plants reported for their use in treatment of ailments related to paralysis in different parts of India. Extensive literature search using Pubmed, Medline, Scopus and Google were conducted in order to extract articles related to ethnobotanical surveys in different parts of India.
Anti-paralytic plants from ethnobotanical surveys in India
The extensive literature survey on the use of medicinal plants for paralysis in India showed that relatively few documentation of medicinal plants have been done, and even lesser laboratory authentication and analysis have been done in relation to the applicability in paralysis. Among the total of 29 (Fig. 1) . Nine different plant parts were found to be used for various treatment of the ailment. In most of the cases, the leaves are mostly used, followed by roots, seeds, whole plants, stem, barks, fruit, flower head and bulb respectively (Fig. 2) . Amongst the 37 plants reported, 11 plants are reported for their ability to cure paralysis (Table 2 ). However, in most of the ethnobotanical studies, the information mentioned and documented are inadequate, wherein the use of the plant, the mode of use, the methods of preparation, dosage, durations, specificity, effectiveness and contradictions are not discussed in details. In addition the type of paralysis (whether localized or general paralysis, monoplegia, hemiplegia, paraplegia or tetraplegia) for which the plants is used is mentioned only in 6 plants ( 
Laboratory studies on plants used in paralysis
In the last decades few laboratory studies have been conducted to understand the efficacy of medicinal plants for their application in ailments related to nerve injury or functions. Maryam Tehranipour and Tooba Ghadamyari reported that alcoholic root extract of Salvia staminea could increase neuronal density of motoneurons in anterior horn of spinal cord following sciatic nerve compression. 80 Spinal cord ischemia/reperfusion (I/R) injury may lead to immediate or delayed paraplegia in 4%e33% of patients undergoing surgery on the thoracic aorta. 81 Therefore, in an attempt to prevent any undesired complications, various methods of spinal cord protection have been suggested, including temporary shunts or partial bypass, hypothermia, drainage of cerebrospinal fluid, and pharmacologic measures. 82e84 Despite the use of these methods, paraplegia remains a persistent complication. 85 Tetramethylpyrazine (TMP), also called ligustrazine, is an alkaloid extracted from the Chinese herbal medicine, Ligusticum wallichii (chuanxiong). 86 For hundreds of years, TMP has been routinely used for the treatment of heart, kidney, and brain diseases. 33, 87, 88 Spinal cord I/R induce significant increase in the concentration of malondialdehyde (MDA) in the spinal cord, indicating lipid peroxidation. 89 Studies showed that TMP treatment reverse the increase in MDA levels to a considerable extent, and ameliorated the down regulation of spinal cord superoxide dismutase (SOD) activity, thereby confirming the antioxidant role of TMP in I/R. 22 In animals that had significant impairment of motor function, evidence of both necrosis and apoptosis was apparent. The Bcl-2 proteins comprise both anti-apoptotic family members, for example, Bcl-2, Bcl-xL, and Mcl-1, and proapoptotic molecules such as Bax, Bak, and BH3 domain only molecules. The ratio of anti-to proapoptotic molecules such as Bcl-2/Bax determines the response to a death signal. 23 In addition, over-expression of Bcl-2 may play a protective role in neuropathological sequelae after central nervous system (CNS) insults. 24 It was shown that treatment with TMP upregulated the level of the anti-apoptotic protein Bcl-2 and downregulated pro-apoptotic protein Bax, suggesting that TMP exhibit an inhibitory effect on apoptotic cell death due to spinal cord I/R through modulation of Bcl-2 family. Thus, TMP treatment could increase the proportion of animals with normal motor function, and in these animals, necrosis was decreased and more normal motoneurons were preserved. 22 Acute spinal cord injury (SCI) caused by motor vehicle accidents, sports injuries, diving accidents and violence, is one of the most common and devastating injuries encountered at the spine surgery department. SCI injury has a high rate of prevalence in the younger population, and causes permanent disability or lost of movement and sensation. 25, 26 Many studies have shown that injury induced inflammation can result in neuropathology and secondary necrosis after traumatic SCI. 27e29 Inflammation plays an important role in the progressive secondary injury that causes neurological deficits. 30 Some studies have shown that the treatment between the primary and the secondary injury of SCI has the potential to either prevent or reduce the final neurological deficits. 31, 32 TMP have been shown to have the ability to reduce cerebral ischemia/reperfusion injury through suppression of inflammatory cell activation and proinflammatory cytokine production, 33, 35 and accelerate spinal cord repair through up-regulating neurofilament protein expression and down-regulating caspase-3 expression following contusion SCI. 36 Traumatic SCI has been reported to activate nuclear factor-kappa B (NF-kB), a transcriptional factor. Hence, knockdown of NF-kB in vivo could have the ability to improve function recovery after SCI. 27, 37 In normal conditions, the NF-kB is combined with inhibitor of kappa-Ba (I-kBa) in the cytoplasm, and does not have transcriptional activity. 38 Another study on TMP reported activation of NF-kB after SCI, which could be inhibited by TMP treatment. However, it was observed that the expression of I-kBa was increased by TMP treatment, suggesting that TMP might have inhibited NF-kB activation through increasing the expression of IkBa. 39 Alpinia katsumadai is a plant used in traditional Chinese medicine. The extract of Alpinia katsumadai seed (EAKS) suppressed topical pruritis, showed anti-inflammatory effects, and enhanced antioxidant activity in several studies. 40, 41 It has been reported that repeated oral administration of EAKS protects neurons from ischemic damage in the hippocampus, associated with an upregulation of brain-derived neurotrophic factor (BDNF), a neurotrophic factor in ischemic areas. 42 From these findings with deeper research on bioactive compounds derived from medicinal plants, the cure for paralysis could be achievable in the near future.
Current status of drugs used in paralysis
Current major treatment for SCI is the use of high doses of methylprednisolone (MP), which reduces edema of the spinal cord and secondary damages. However, MP has numerous side effects, and its therapeutic effects are controversial. There is insufficient evidence to support the use of MP as a standard treatment for acute SCI. 43 Also treatment using MP is controversially, as prolonged or delayed treatment, incorrect dosing or treatment of penetrating SCI has been shown to be detrimental. 44, 45 A recent review on randomized trials examined whether modest improvements have been shown using MP, monosialotetrahexosylganglioside (GM-1) ganglioside, thyrotropin-releasing hormone (TRH), nimopidine and the NMDA (N-methyl-D-aspartate) antagonist gacyclidine, 46 where it was concluded that, in most trials, primary outcome measures
were not significant and placebo controls were lacking. 46 Several studies have also recently reported that intravenous minocycline reduces cell death and improves hindlimb function in mouse and rat models of SCI, 34, 48, 49 and is expected to progress to clinical trials for SCI. 89 A study on Nebivolol (selective b-adrenergic blocking agent) showed that it prevented the increase in enzymatic activities of superoxide dismutase (SOD), xanthine oxidase (XO), adenosine deaminase (ADA) and myeloperoxidase (MPO) produced by I/R, and also prevented the decrease in spinal cord glutathione peroxidase (GSH-Px) level in I/R, thereby implicating its useful application in preventing secondary injury of nerves. 90 Many people with a spinal cord injury, and some with other types of paralysis, have long-term pain that persists for weeks, months, or sometimes years after the injury or incident that caused the paralysis. Unlike most other types of pain, neuropathic pain does not usually respond well to ordinary painkillers, such as paracetamol or ibuprofen. Alternative medications are usually required, such as amitriptyline or pregabalin. These types of medication can cause a wide range of side effects. Possible side effects include a dry mouth, sweating, drowsiness and vision problems. Reports are also available about people having suicidal thoughts while taking amitriptyline.
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Thus, there still is urgent need for the development of highly effective and safe neuroprotective therapies for human.
Conclusion
The search for paralysis is one of the greatest challenges in medical research. The greatest challenge is to develop means for restoring movement and sensation, and elimination of pain for people with paralysis. Currently, apart from hunting for drugs that can help in restoring paralyzed nerves, various other interventions have been on the limelight with the same goal. Various researchers are also working extensively on the application of electrical stimulation as well as optical and magnetic techniques for activating the neural tissue below the level of injury. Other areas of approach includes surgical interventions, but none of these practices are able to provide total or complete recovery of the injured nerves, and in many cases not very cost effective for common applications. In addition, these approaches and the lacunae associated with them are further complicated by the unavailability of simple protocols, test and assays to experiment them, which also could have accounted for the slow pace in advancement in this field of research. For instance till date there is no simple in vitro assay to test the potential applicability of any compounds or drugs against any type of paralysis, since in reports available so far, complicated processes are followed that use rats or mouse for researches related to paralysis. One way of approach could be by devising techniques that can use cultured neuronal cell lines, in which direct assay and experiments could be conducted without the need to use model animal. Such techniques, if developed, would help in simplifying Bombax ceiba Linn.
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